clinical trial · NCT06673667
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
Healthy Participants StudyKT-621Placebo
brief summary
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
started
Oct 22, 2024
primary completion
Apr 23, 2025
completion
Apr 23, 2025
last updated
Oct 2, 2025
official title
A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-621 in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol